Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Status: Recruiting
Location: See all (62) locations...
Study Type: Observational
SUMMARY
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Participants who signed ICF
• Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
• Participants who are starting or are already being treated with systemic therapy
Locations
United States
Florida
Holy Cross Health
RECRUITING
Fort Lauderdale
Ohio
The Ohio State University Wexner Medical Center
RECRUITING
Columbus
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Other Locations
Austria
Klinikum Klagenfurt Am Woerthersee
RECRUITING
Klagenfurt
Klinik Floridsdorf
RECRUITING
Vienna
Belgium
AZ Delta
RECRUITING
Roeselare
AZ Nikolaas
RECRUITING
Sint-niklaas
Canada
Ottawa Hospital General Campus
RECRUITING
Ottawa
Princess Margaret Cancer Centre
RECRUITING
Toronto
Finland
University Hospital of Tampere
NOT_YET_RECRUITING
Tampere
Turun Yliopistollinen Keskussairaala
NOT_YET_RECRUITING
Turku
France
Centre Hospitalier de Cholet
RECRUITING
Cholet
CHRU Lille
RECRUITING
Lille
Hôpital du Scorff
RECRUITING
Lorient
Centre Leon Berard
RECRUITING
Lyon
Hospital Tenon & University Paris 6
RECRUITING
Paris
Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
RECRUITING
Paris
CHU de Toulouse Hopital Larrey
RECRUITING
Toulouse
Germany
Klinikum Chemnitz GmbH
RECRUITING
Chemnitz
KKH Grosshansdorf GmbH
RECRUITING
Großhansdorf
Thoraxklinik-Heidelberg gGmbH
RECRUITING
Heidelberg
Klinik Löwenstein GmbH
RECRUITING
Löwenstein
Israel
Haemek Medical Center
RECRUITING
Afula
Assuta Ashdod Medical Center
RECRUITING
Ashdod
Bnei-Zion Medical Center
RECRUITING
Haifa
Carmel Medical Center
RECRUITING
Haifa
Rambam Medical Center - PPDS
RECRUITING
Haifa
Shaare Zedek Medical Center
RECRUITING
Jerusalem
Rabin Medical Center Oncology Beilinson Campus
RECRUITING
Petah Tikva
Chaim Sheba Medical Center
RECRUITING
Ramat Gan
Tel Aviv Sourasky Medical Center
RECRUITING
Tel Aviv
Italy
Istituto Europeo di Oncologia
RECRUITING
Milan
Istituto Nazionale Dei Tumori
RECRUITING
Milan
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
RECRUITING
Napoli
I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
RECRUITING
Rome
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
RECRUITING
Torino
Ospedale di Circolo
RECRUITING
Varese
Netherlands
VU Medisch Centrum
RECRUITING
Amsterdam
Universitair Medisch Centrum Groningen - Department of Medical Oncology
RECRUITING
Groningen
Leiden University Medical Center
RECRUITING
Leiden
Portugal
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
RECRUITING
Lisbon
Centro Hospitalar do Porto E.P.E. Hospital de Santo António
RECRUITING
Porto
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
RECRUITING
Porto Covo
Spain
Clinica Tres Torres
RECRUITING
Barcelona
Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
RECRUITING
Barcelona
Complejo Hospitalario Universitario Insular-Materno Infantil
RECRUITING
Las Palmas De Gran Canaria
Centro Integral Oncologico Clara Campa
RECRUITING
Madrid
Centro Oncologico MD Anderson
RECRUITING
Madrid
Hospital Regional Universitario de Malaga - Hospital General
RECRUITING
Málaga
Hospidal Universitario Ntra. Sra. De Valme
RECRUITING
Seville
Hospital Universitario Virgen Macarena
RECRUITING
Seville
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITING
Valencia
Sweden
Universitetssjukhuset i Linköping
RECRUITING
Linköping
United Kingdom
Bedford General Hospital
RECRUITING
Bedford
Birmingham Heartlands Hospital
RECRUITING
Birmingham
Royal Bournemouth Hospital
RECRUITING
Bournemouth
The Royal Marsden Hospital
RECRUITING
Chelsea
Royal Surrey County Hospital
RECRUITING
Guildford
Northwick Park Hospital
RECRUITING
Harrow
Clatterbridge Cancer Centre - Liverpool
RECRUITING
Liverpool
Charing Cross Hospital
RECRUITING
London
Preston Hospital
RECRUITING
Preston
Contact Information
Primary
US Medical Information
eMediUSA@emdserono.com
888-275-7376
Backup
Communication Center
service@emdgroup.com
+49 6151 72 5200
Time Frame
Start Date: 2022-10-04
Estimated Completion Date: 2028-04-28
Participants
Target number of participants: 700
Treatments
Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
Related Therapeutic Areas
Sponsors
Collaborators: Merck KGaA, Darmstadt, Germany
Leads: EMD Serono Research & Development Institute, Inc.